These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 32448798)

  • 1. Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy.
    Eckstein M; Strissel P; Strick R; Weyerer V; Wirtz R; Pfannstiel C; Wullweber A; Lange F; Erben P; Stoehr R; Bertz S; Geppert CI; Fuhrich N; Taubert H; Wach S; Breyer J; Otto W; Burger M; Bolenz C; Keck B; Wullich B; Hartmann A; Sikic D;
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of stromal tumor infiltrating lymphocyte scoring (sTILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy.
    Sikic D; Weyerer V; Geppert CI; Bertz S; Lange F; Taubert H; Wach S; Schmitz-Draeger BJ; Wullich B; Hartmann A; Eckstein M
    Urol Oncol; 2022 Feb; 40(2):63.e19-63.e26. PubMed ID: 34420870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.
    Pfannstiel C; Strissel PL; Chiappinelli KB; Sikic D; Wach S; Wirtz RM; Wullweber A; Taubert H; Breyer J; Otto W; Worst T; Burger M; Wullich B; Bolenz C; Fuhrich N; Geppert CI; Weyerer V; Stoehr R; Bertz S; Keck B; Erlmeier F; Erben P; Hartmann A; Strick R; Eckstein M; ; ; ;
    Cancer Immunol Res; 2019 Jun; 7(6):923-938. PubMed ID: 30988029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.
    van Kessel KE; van de Werken HJ; Lurkin I; Ziel-van der Made AC; Zwarthoff EC; Boormans JL
    PLoS One; 2017; 12(3):e0174039. PubMed ID: 28319171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Sjödahl G; Abrahamsson J; Holmsten K; Bernardo C; Chebil G; Eriksson P; Johansson I; Kollberg P; Lindh C; Lövgren K; Marzouka NA; Olsson H; Höglund M; Ullén A; Liedberg F
    Eur Urol; 2022 May; 81(5):523-532. PubMed ID: 34782206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
    McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
    Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of
    Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.
    Fu H; Zhu Y; Wang Y; Liu Z; Zhang J; Xie H; Fu Q; Dai B; Ye D; Xu J
    Clin Cancer Res; 2018 Jul; 24(13):3069-3078. PubMed ID: 29514839
    [No Abstract]   [Full Text] [Related]  

  • 10. CD19
    Jiang Q; Fu Q; Chang Y; Liu Z; Zhang J; Xu L; Zhu Y; Wang Y; Zhang W; Xu J
    Cancer Immunol Immunother; 2019 Jan; 68(1):45-56. PubMed ID: 30259082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
    Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
    BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
    Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
    Yan S; Zeng H; Jin K; Shao F; Liu Z; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Xu J
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35523436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis.
    Koll FJ; Banek S; Kluth L; Köllermann J; Bankov K; Chun FK; Wild PJ; Weigert A; Reis H
    J Transl Med; 2023 Feb; 21(1):124. PubMed ID: 36793050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer.
    Sun M; Zeng H; Jin K; Liu Z; Hu B; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
    Cancer Immunol Immunother; 2022 Jun; 71(6):1497-1506. PubMed ID: 34716763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study.
    Chauhan PS; Chen K; Babbra RK; Feng W; Pejovic N; Nallicheri A; Harris PK; Dienstbach K; Atkocius A; Maguire L; Qaium F; Szymanski JJ; Baumann BC; Ding L; Cao D; Reimers MA; Kim EH; Smith ZL; Arora VK; Chaudhuri AA
    PLoS Med; 2021 Aug; 18(8):e1003732. PubMed ID: 34464379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of consensus molecular subtypes on survival with and without adjuvant chemotherapy in muscle-invasive urothelial bladder cancer.
    Koll FJ; Döring C; Herwig L; Hoeh B; Wenzel M; Cano Garcia C; Banek S; Kluth L; Köllermann J; Weigert A; Chun FK; Wild P; Reis H
    J Clin Pathol; 2024 Dec; 78(1):19-27. PubMed ID: 37989554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis.
    de Jong JJ; Liu Y; Robertson AG; Seiler R; Groeneveld CS; van der Heijden MS; Wright JL; Douglas J; Dall'Era M; Crabb SJ; van Rhijn BWG; van Kessel KEM; Davicioni E; Castro MAA; Lotan Y; Zwarthoff EC; Black PC; Boormans JL; Gibb EA
    Genome Med; 2019 Oct; 11(1):60. PubMed ID: 31619281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
    Liu Z; Zeng H; Jin K; Yu Y; You R; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
    Br J Cancer; 2022 May; 126(9):1310-1317. PubMed ID: 35039625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin
    Zhou Q; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Liu L; Zhu Y; Xu L; Dai B; Guo J; Xia Y; Wang Y; Xu J
    Oncoimmunology; 2020 Apr; 9(1):1747333. PubMed ID: 33457092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.